Characteristics of the CLL Patients
| Patient . | Age (yr) . | Sex . | Rai Stage . | Disease Activity . | WBC Count (×109/L) . | Total T-cell Counts (×109/L)* . | ||
|---|---|---|---|---|---|---|---|---|
| CD3+ . | CD4+ . | CD8+ . | ||||||
| CLL 2 | 67 | F | III | PD | 212.0 | 2.12 | 1.21 | 0.74 |
| CLL 3 | 38 | F | 0 | NPD | 30.0 | 4.20 | 2.39 | 1.81 |
| CLL 7 | 81 | M | I | PD | 30.0 | 0.90 | 0.31 | 0.55 |
| CLL 9 | 63 | M | 0 | NPD | 14.0 | 2.24 | 0.90 | 1.34 |
| CLL 10 | 62 | F | I | NPD | 24.1 | 1.70 | 1.05 | 0.63 |
| CLL 11 | 68 | F | I | NPD | 83.2 | 17.47 | 12.41 | 4.72 |
| CLL 13 | 75 | F | II | PD | 71.2 | 1.42 | 0.80 | 0.62 |
| CLL 14 | 82 | F | III | NPD | 37.1 | 0.74 | 0.27 | 0.33 |
| CLL 15 | 77 | F | III | PD | 137.9 | 2.76 | 1.23 | 1.53 |
| CLL 16 | 81 | M | II | PD | 326.0 | 4.89 | 1.86 | 3.00 |
| Patient . | Age (yr) . | Sex . | Rai Stage . | Disease Activity . | WBC Count (×109/L) . | Total T-cell Counts (×109/L)* . | ||
|---|---|---|---|---|---|---|---|---|
| CD3+ . | CD4+ . | CD8+ . | ||||||
| CLL 2 | 67 | F | III | PD | 212.0 | 2.12 | 1.21 | 0.74 |
| CLL 3 | 38 | F | 0 | NPD | 30.0 | 4.20 | 2.39 | 1.81 |
| CLL 7 | 81 | M | I | PD | 30.0 | 0.90 | 0.31 | 0.55 |
| CLL 9 | 63 | M | 0 | NPD | 14.0 | 2.24 | 0.90 | 1.34 |
| CLL 10 | 62 | F | I | NPD | 24.1 | 1.70 | 1.05 | 0.63 |
| CLL 11 | 68 | F | I | NPD | 83.2 | 17.47 | 12.41 | 4.72 |
| CLL 13 | 75 | F | II | PD | 71.2 | 1.42 | 0.80 | 0.62 |
| CLL 14 | 82 | F | III | NPD | 37.1 | 0.74 | 0.27 | 0.33 |
| CLL 15 | 77 | F | III | PD | 137.9 | 2.76 | 1.23 | 1.53 |
| CLL 16 | 81 | M | II | PD | 326.0 | 4.89 | 1.86 | 3.00 |
Abbreviation: WBC, white blood cell.
At the time when the T cell repertoire was analyzed.